期刊文献+

无定形态药物结晶行为的研究进展 被引量:11

Recent progress on crystallizations of amorphous pharmaceutical solids
下载PDF
导出
摘要 无定形态药物与其晶态形式相比较,通常具有更高的溶解度和更快的溶出速率,并有效地改善部分难溶性药物的口服生物利用度。但由于无定形态药物处于热力学不稳定的高自由能状态,容易自发转变为其热力学稳定的晶态形式,从而丧失其原有优势。本文简述了无定形态药物中存在的多种快速结晶行为,并介绍近几年来该领域的研究进展。通过对无定形药物结晶内在机制的研究,有助于人们更好地理解、控制和预测无定形态药物的物理稳定性,为合理有效的开发无定形药物制剂提供理论基础。 Compared to their crystalline form,amorphous drugs exhibit higher solubility and faster dissolution rate and thus enhancing oral bioavailability of poorly water soluble drugs.However,since the amorphous form is thermodynamically unstable relative to the crystalline form,amorphous solids tend to crystallize over time and subsequently negate their advantages.This review briefly describes fundamental aspects of amorphous substances and highlights the recent advances of fast crystallization behaviors.Understanding the inherent crystallization mechanisms of amorphous materials is of utmost importance in order to control the physical stability and lead to efficient formulation development of amorphous pharmaceutical solids.
作者 施秦 蔡挺
出处 《中国药科大学学报》 CAS CSCD 北大核心 2017年第6期654-662,共9页 Journal of China Pharmaceutical University
基金 国家自然科学基金资助项目(No.81402877) 江苏省双创团队计划 天然药物活性组分与药效国家重点实验室优秀青年人才基金项目(No.SKLNMZZYQ201604) 江苏省高校研究生科研创新计划项目(No.KYLX16_1180)~~
关键词 无定形药物 结晶 表面 玻璃态 分子运动 稳定性 amorphous drugs crystallization surface glass molecular mobility stability
  • 相关文献

参考文献5

二级参考文献86

  • 1司岩,石佾.贝尔纳与贝尔纳效应[J].科学学与科学技术管理,1987,8(4):43-43. 被引量:2
  • 2Rolf H. Polymorphism in the Pharmaceutical Industry [M]. Weinheim: WlLEY-VCH Verlag GmbH & Co. KgaA Press, 2000:259-281.
  • 3Kerc J, Srcic S, Mohar M, et al. Some physicochemical properties of glassy felodipine [J]. Int J Pharm, 1991, 68: 25-33.
  • 4Johari GP, Ram S, Astl G .Characterizing amorphous and microcrystalline solids by calorimetry [J]. J Non-Cryst Solids, 1990, 116: 282-285.
  • 5Mishima O, Calvert LD, Whalley E. An apparently firstorder transition between two amorphous phases of ice induced by pressure [J]. Nature, 1985, 314: 76-78.
  • 6Chokshi R J, Zia H, Sandhu HK, et al. Improving the dissolution rate of poorly water soluble drug by solid dispersion and solid solution: pros and cons [J]. Drug Deliv, 2007, 14: 33-45.
  • 7Matsunaga N, Nakamura K, Yamamoto A, et al. Improvement by solid dispersion of the bioavailability of KRN633, a selective inhibitor of VEGF receptor-2 tyrosine kinase, and identification of its potential therapeutic window [J]. Mol Cancer Ther, 2006, 5: 80-88.
  • 8Dharmendra S, William C. Drug polymorphism and dosage form design: a practical perspective [J]. Adv Drug Deliv Rev, 2004, 56: 335-347.
  • 9Albano AA, Phuapradit W, Sandhu HK, et al. Amorphous form of cell cycle inhibitor having improved solubility and bioavailability: US, 6482847[P]. 2002-11-19.
  • 10Shikura T, Ishizawa T, Suemune K, et al. Amorphous substance of tricyclic triazolobenzazepine derivative: US, 7229985 [P]. 2007-06-12.

共引文献390

同被引文献75

引证文献11

二级引证文献38

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部